Alterations in metabolome and lipidome in patients with in-stent restenosis

被引:1
|
作者
Xu, Ziqi [1 ]
Mou, Chenye [1 ]
Ji, Renjie [1 ]
Chen, Hanfen [1 ]
Ding, Yuge [1 ]
Jiang, Xiaoyi [1 ]
Meng, Fanxia [1 ]
He, Fangping [1 ]
Luo, Benyan [1 ]
Yu, Jie [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Neurol, Hangzhou 310003, Peoples R China
关键词
biomarkers; in-stent restenosis; lipidomics; metabolomics; methionine; INTRACRANIAL ATHEROSCLEROSIS; OXIDATIVE STRESS; AMINO-ACIDS; PHOSPHOLIPIDS; PREVALENCE; PATHWAYS; STENOSIS; CHINA; RISK;
D O I
10.1111/cns.14832
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
ContextIn-stent restenosis (ISR) can lead to blood flow obstruction, insufficient blood supply to the brain, and may even result in serious complications such as stroke. Endothelial cell hyperproliferation and thrombosis are the primary etiologies, frequently resulting in alterations in intravascular metabolism. However, the metabolic changes related to this process are still undermined.ObjectiveWe tried to characterize the serum metabolome of patients with ISR and those with non-restenosis (NR) using metabolomics and lipidomics, exploring the key metabolic pathways of this pathological phenomenon.ResultsWe observed that the cysteine and methionine pathways, which are associated with cell growth and oxidative homeostasis, showed the greatest increase in the ISR group compared to the NR group. Within this pathway, the levels of N-formyl-l-methionine and L-methionine significantly increased in the ISR group, along with elevated levels of downstream metabolites such as 2-ketobutyric acid, pyruvate, and taurocholate. Additionally, an increase in phosphatidylcholine (PC) and phosphatidylserine (PS), as well as a decrease in triacylglycerol in the ISR group, indicated active lipid metabolism in these patients, which could be a significant factor contributing to the recurrence of blood clots after stent placement. Importantly, phenol sulfate and PS(38:4) were identified as potential biomarkers for distinguishing ISR, with an area under the curve of more than 0.85.ConclusionsOur study revealed significant metabolic alterations in patients with ISR, particularly in the cysteine and methionine pathways, with phenol sulfate and PS(38:4) showing promise for ISR identification. Metabolomic and lipidomic analysis showed that patients who developed in-stent restenosis (ISR) had significantly increased expression of L-methionine and N-formyl-l-methionine, and significantly decreased expression of triacylglycerol in their serum. Phenol sulfate and PS(38:4) may be potential biomarkers for the diagnosis of ISR.image
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Hyperglycemia Drives In-Stent Restenosis in STEMI Patients
    Mone, Pasquale
    Gambardella, Jessica
    Pansini, Antonella
    Minicucci, Fabio
    Mauro, Ciro
    Santulli, Gaetano
    CIRCULATION, 2021, 144
  • [22] Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis
    Nakamura, Daisuke
    Dohi, Tomoharu
    Ishihara, Takayuki
    Kikuchi, Atsushi
    Mori, Naoki
    Yokoi, Kensuke
    Shiraki, Tatsuya
    Mizote, Isamu
    Mano, Toshiaki
    Higuchi, Yoshiharu
    Yamada, Takahisa
    Nishino, Masami
    Sakata, Yasushi
    EUROINTERVENTION, 2021, 17 (06) : 489 - +
  • [23] Primarily extravascular cells in in-stent restenosis and in in-stent restenosis after intracoronary bachytherapy
    Bauriedel, G
    Skowasch, D
    Jabs, A
    Dinkelbach, S
    Schiele, TM
    Lüderitz, B
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 43A - 43A
  • [24] Treatment of In-Stent Restenosis in Patients with Renal Artery Stenosis
    Takahashi, Edwin A.
    McKusick, Michael A.
    Bjarnason, Haraldur
    Piryani, Ameet
    Harmsen, William S.
    Misra, Sanjay
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 27 (11) : 1657 - 1662
  • [25] Predictors of early in-stent restenosis
    Pershukov, IV
    Niyazova-Karben, ZA
    Batyraliev, TA
    Preobrazhenskiy, DV
    Sercelik, A
    Guler, N
    Eryonucu, B
    Kadayifci, S
    Ozgul, S
    Akgul, F
    Temamogullari, A
    Demirbas, O
    Sengul, H
    Dogru, I
    Petrakova, L
    Sidorenko, BA
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (6A): : 207L - 208L
  • [26] Current Management of In-Stent Restenosis
    Her, Ae-Young
    Shin, Eun-Seok
    KOREAN CIRCULATION JOURNAL, 2018, 48 (05) : 337 - 349
  • [27] In-stent restenosis: Therapy and prevention
    Radke, PW
    vom Dahl, J
    Klues, HG
    MEDIZINISCHE KLINIK, 1999, 94 (02) : 88 - 92
  • [28] Laser angioplasty of in-stent restenosis
    Koster, RP
    Koschyk, DH
    Kahler, J
    Steffen, W
    Terres, W
    Hamm, CW
    CIRCULATION, 1996, 94 (08) : 3637 - 3637
  • [29] In-stent restenosis: Pathophysiology and treatment
    Looser P.M.
    Kim L.K.
    Feldman D.N.
    Current Treatment Options in Cardiovascular Medicine, 2016, 18 (2)
  • [30] Therapeutic Options for In-Stent Restenosis
    Nicolais, Charles
    Lakhter, Vladimir
    Virk, Hafeez Ul Hassan
    Sardar, Partha
    Bavishi, Chirag
    O'Murchu, Brian
    Chatterjee, Saurav
    CURRENT CARDIOLOGY REPORTS, 2018, 20 (02)